Cartilage News and Research

RSS

Cartilage is a stiff yet flexible connective tissue found in many areas in the bodies of humans and other animals, including the joints between bones, the rib cage, the ear, the nose, the elbow, the knee, the ankle, the bronchial tubes and the intervertebral discs.

Osiris: CMS releases proposed ruling for reimbursement of skin substitutes in hospital outpatient setting

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products in orthopedics, sports medicine and wound care, announced today that, on November 27, 2013, the Centers for Medicare and Medicaid Services released their proposed ruling for the reimbursement of skin substitutes in the hospital outpatient setting. CMS decided to package the reimbursement for products used in advanced wound care with the related surgical procedure into a two-tier system.

30 Nov 2013

Inhibition of complement system plays major role in xenograft rejection

Researchers at the Bellvitge Institute of Biomedical Research (IDIBELL) led by Cristina Costa from the New Therapies on Genes and Transplantation group have shown that inhibition of one of the basic components of the complement system protects chondrocytes (cartilage cells) from porcine rejection of xenotransplantation (transplantation between animals of different species).

27 Nov 2013

Knee surgery for type of meniscus tear can involve difficult tradeoff

Knee surgery for the type of meniscus tear suffered by Chicago Bulls star Derrick Rose can involve a difficult tradeoff, according to Loyola sports medicine surgeon Dr. Pietro Tonino, who has performed thousands of knee surgeries.

26 Nov 2013

Research sheds light on how protein keeps people organized by promoting orderly skeletal growth

Most people think that their planners or their iPhones keep them organized, when proteins such as liver kinase b1 (Lkb1) actually have a lot more to do with it. New research from postdoctoral fellow Lick Lai in the lab of USC scientist Andy McMahon published in Proceedings of the National Academy of Sciences (PNAS) sheds light on how this important protein keeps people organized on a basic level by promoting orderly skeletal growth and preventing skeletal tumors.

15 Nov 2013

Medical researchers discover structure of potential drug target for rare genetic disease

Medical researchers at the University of Alberta have discovered the structure of a potential drug target for a rare genetic disease, paving the way for an alternative treatment for the condition.

15 Nov 2013

Radiofrequency neurotomy may be successful alternative treatment for knee osteoarthritis

Chronic knee osteoarthritis is the deterioration of articular cartilage and is one of the most common diseases of aging. Millions of Americans have been diagnosed with knee osteoarthritis. OA often results in pain, restricted movement, sleep disturbance, and functional disability.

14 Nov 2013

Researchers able to regrow bone, hair, soft tissues and cartilage in mouse model

Young animals are known to repair their tissues effortlessly, but can this capacity be recaptured in adults? A new study from researchers at the Stem Cell Program at Boston Children's Hospital suggests that it can. By reactivating a dormant gene called Lin28a, which is active in embryonic stem cells, researchers were able to regrow hair and repair cartilage, bone, skin and other soft tissues in a mouse model.

8 Nov 2013

Scientists to develop on-demand drug-delivery system for pain management in osteoarthritis patients

Scientists are reporting development of a squishy gel that when compressed - like at a painful knee joint - releases anti-inflammatory medicine. The new material could someday deliver medications when and where osteoarthritis patients need it most. Their study appears in the ACS journal Biomacromolecules.

8 Nov 2013

Cellular Biomedicine Group gets approval to conduct ReJoin Phase IIb trial for Knee Osteoarthritis

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that it has received approval to conduct a Phase IIb clinical trial for ReJoin, a human adipose-derived mesenchymal precursor cells (haMPC) therapy bio-engineered for Knee Osteoarthritis.

5 Nov 2013

Potential, low-cost approach to improve exercise adherence in knee osteoarthritis patients

New research presented at the American College of Rheumatology Annual Meeting in San Diego describes an exciting novel tool utilizing telephone linked technology that shows potential as a low cost approach to improving exercise adherence in patients with knee osteoarthritis.

28 Oct 2013

Patellofemoral knee brace can improve pain, bone marrow lesions in knee osteoarthritis patients

Use of a patellofemoral knee brace can improve pain symptoms and bone marrow lesions in patients with a type of osteoarthritis of the knee, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Scientists work hard to improve procedures for artificially producing tissue

What sounds like a dream of the future has already been the subject of research for a few years: simply printing out tissue and organs. Now scientists have further refined the technology and are able to produce various tissue types.

25 Oct 2013

Tissue-engineered transplants safe and effective in the long term: Study

New results published in The Lancet today [Wednesday 23 October] reveal that five years after the first successful transplantation of a tissue-engineered airway (reported in The Lancet in 2008) the recipient continues to enjoy a good quality of life, and has not experienced any immunological complications or rejection of the implanted airway.

23 Oct 2013

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis who have used one or more disease-modifying antirheumatic drugs, such as methotrexate, that did not provide enough relief.

22 Oct 2013

UCLA study uncovers biological clock that may shed light on why our bodies age

Everyone grows older, but scientists don't really understand why. Now a UCLA study has uncovered a biological clock embedded in our genomes that may shed light on why our bodies age and how we can slow the process.

21 Oct 2013

New research identifies internal timepiece that accurately gauge age of human organs and tissues

21 Oct 2013

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice daily in people with active rheumatoid arthritis (RA) taking methotrexate

19 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Scientists develop new method to regenerate cartilage

Unlike our bones, the cartilage inside our joints is not vascularized (i.e., it has no blood vessels). This is one reason why cartilage does not heal well after an injury. In athletes in particular, joint injuries often result in cartilage degeneration and arthritis. The process is chronic and irreversible, and to this day, no effective treatment exists.

12 Oct 2013

Osiris Therapeutics agrees to sell ceMSC business to Mesoblast

Osiris Therapeutics, Inc. announced today that it has entered into an agreement with a wholly-owned subsidiary of Mesoblast Limited for the sale of Osiris' culture-expanded mesenchymal stem cell business, including Prochymal, in a transaction worth up to $100 million in initial consideration and milestone payments.

11 Oct 2013